Home › Oligomerix Awarded A Grant For Its Alzheimer's Drug Discovery Program Targeting Tau Oligomers From The National Institutes Of Health
 

Keywords :   


Oligomerix Awarded A Grant For Its Alzheimer's Drug Discovery Program Targeting Tau Oligomers From The National Institutes Of Health

2016-05-03 02:45:01| drugdiscoveryonline News Articles

Oligomerix, Inc., a privately held company targeting tau oligomers for developing disease modifying therapeutics for Alzheimer’s disease (AD) and related neurodegenerative disorders, announced recently the receipt of an award for a Direct-to-Phase-II Small Business Innovation Research (SBIR) grant for a two year program for a total of $1.5 M from the National Institutes of Health (NIH), National Institute on Aging (NIA)

Tags: of health program national

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
12.05Is social media worth paying for?
12.05Switzer Ranch staying resilient with long-term outlook
12.05BIF announces Seedstock, Commercial Producer award finalists
11.05Weekly Recap: Hempel, Sherwin-Williams Top This Weeks Stories
11.05LG CHI Color Master Factory Is Awarded Patent
11.05AgriWebb raises $7.2m to fuel further innovation in sustainable beef production
11.05YouGov Unveils Americans Skincare Routines
11.05Naples Soap Company Reports Revenue Surge Amidst Tourist Season
More »